| Abstrakt: |
A recent study conducted by researchers at the University of South Carolina has identified a novel cyclic peptide called CycloAnt, which shows promise as a safer and more effective analgesic for pain treatment. The peptide demonstrated dose- and time-dependent antinociception mediated by the mu-opioid receptor (MOR), and higher doses also antagonized delta-opioid receptors (DOR). Importantly, CycloAnt did not reduce breathing rate or induce hyperlocomotion, suggesting a reduced risk of side effects compared to morphine. While tolerance was observed with chronic administration, CycloAnt showed reduced physical dependence and opioid-induced hyperalgesia compared to morphine. These findings suggest that CycloAnt could be a valuable lead for the development of peptide-based safer analgesics. [Extracted from the article] |
